T2 Candida Panel is Superior to Blood Cultures for Identifying Candidemia

Candida albicans
Candida albicans
Compared to blood cultures, T2 Candida Panel is faster and more sensitive in detecting Candidemia.
This article is part of Infectious Disease Advisor’s coverage of IDWeek 2017™, taking place in San Diego, CA. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from IDWeek 2017.

SAN DIEGO – The T2 Candida panel is highly sensitive and provides faster identification of candidemia compared with using blood culture tests, according to a poster abstract presented at IDWeek 2017.

Researchers performed a prospective, observational analysis of 345 patients to determine the diagnostic differences between the T2 Candida panel and blood culture tests for the identification of candidemia. The panel was used only for patients with febrile neutropenia, recent antibiotic use, acute pancreatitis, recent major surgery, renal failure/hepatic failure, corticosteroid use and unexplained fever, and for those who stayed in the intensive care unit (ICU) for more than 72 hours.

In total, 78% of patients were admitted to the ICU. T2 Candida tests were positive in 9% of patients included in this analysis. The tests identified the Candida albicans/tropicalis (47%), C parapsilosis (41%), and C glabrata/krusei (12%) species. Only 24% of patients with a positive T2 Candida test result also had a positive corresponding blood culture, whereas positive blood culture results correlated with 94.9% of positive T2 results.

The discontinuation of antifungal therapy was observed in 23% of patients with a negative T2 Candida test result; however, approximately 36% of patients with a negative T2 Candida result continued their regular antifungal therapy regimen. There was an average 2.1-day decrease in the duration of micafungin use among patients with negative T2 Candida results.

Related Articles

Blood cultures can take 2 to 6 days to obtain results and often fail to detect 40% to 50% of Candida infections. The T2 Candida panel, however, provides “rapid (3-5 hours) species-specific detection of Candida species,” noted the investigators.

Despite the rapid nature and higher sensitivity of the panel test, the time “to de-escalation remains at 2 days, suggesting variations in physicians’ utilization of T2 Candida test results,” concluded the researchers.

Visit Infectious Disease Advisor’s conference section for continuous coverage live from IDWeek 2017.


Hassoun A, Abdulhaleem M, Edwards J. Utilization of the T2 Candida panel for rapid Candida species detection in a large community hospital. Presented at: IDWeek 2017; October 4-8, 2017; San Diego, CA. Poster 2066.